Teva Announces Tentative Approval Of Generic Femara(R) Tablets
 

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration (FDA) has granted tentative approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Novartis' breast cancer treatment Femara® (letrozole) Tablets, 2.5 mg...

More...